Alx oncology announces initial data from aspen-05 study of evorpacept in combination with azacitidine and venetoclax, demonstrating tolerability and preliminary activity in patients with acute myeloid leukemia

-- antileukemic activity demonstrated in patients with both relapsed/refractory and newly diagnosed aml -- no evorpacept-related cytopenias observed and no maximum tolerated dose identified in combination with azacitidine and venetoclax
ALXO Ratings Summary
ALXO Quant Ranking